Dr. Stephan Rietiker resigns as Chairman of RepRegen™

LONDON--(BUSINESS WIRE)-- RepRegen, the ‘smart biomaterials’ company, wishes to advise that Stephan Rietiker has resigned as Chairman of RepRegen, effective June 9, 2011. Dr. Rietiker cited “significant and competing workload and responsibilities” as the reason for his resignation. However, he expressed his continued support for RepRegen as the company enters its next phase of growth.

“We wish to thank Stephan for his contribution to RepRegen and for his ongoing support,” said Mr. Ian Brown, RepRegen’s CEO.

About RepRegen™ Ltd

RepRegen is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in vivo. The first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. A spin-out company from Imperial College London, RepRegen is headquartered within the Imperial College Incubator.

RepRegen’s first product is StronBoneTM bone graft substitute bioactive glass with Strontium. StronBone and other products in the “hard tissue repair and regeneration” range are for orthopaedic (trauma and spine) and craniomaxillofacial applications.

RepRegen develops products to repair and restore tissue better and faster. The company’s Smart Biomaterials are designed both to support and to improve cellular growth in vivo. The materials comprise innovations in bioactive ceramics or biomimetic polymer scaffolds. Both product lines have significant competitive advantages, on the one hand, by enhancing cellular growth through topography of scaffolds and on the other hand, by the use of specially selected materials.

Note: In the EU, StronBone Bone Graft Substitute is a medical device product which has CE Marking approval. In the USA, StronBone Bone Graft Substitute is a medical device product that has not yet been cleared by the FDA and can therefore only be used for investigational use.



CONTACT:

Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1 508-359-4005, x108
[email protected]

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.